EMA to review AstraZeneca’s Forxiga for type-1 diabetes

This article was originally published here

The European Medicines Agency (EMA) has accepted AstraZeneca’s marketing authorisation variation for its selective SGLT-2 inhibitor Forxiga (dapagliflozin) for use as an oral adjunct treatment to insulin in adults with type-1 diabetes (T1D).

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply